Dubravka Cvejic
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Dubravka Cvejic has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
Ivana Petrovic
Institute for the Application of Nuclear Energy – INEP, University of Belgrade, Belgrade, Serbia
5 shared publicationsI Paunovic
4 shared publicationsS Savin
4 shared publicationsS Tatic
4 shared publicationsIvan Paunovic
Centre for Endocrine Surgery, Institute of Endocrinology, Diabetes and Diseases of Metabolism, Clinical Centre of Serbia, Belgrade, Serbia
3 shared publicationsM Havelka
3 shared publications
Latest Publications
- Open Access
- 30 June 2009
- Published by PAGEPress Publications in European Journal of Histochemistry
- Vol. 53 (2) , e8
Changes in the balance between proliferation and apoptosis during the progression of malignancy in thyroid tumours
The aim of this study was to gain better insight into molecular changes which reflect disturbances in the balance between proliferation and apoptosis during progression of thyroid malignancy from papillary microcarcinoma (PMC) via clinically manifest papillary carcinoma (PTC) to anaplastic carcinoma (ATC). The apoptosis related molecules (Bcl-2, Bax) and proliferation related marker (PCNA) were analysed immunohistochemically in 120 archival cases comprising PMC (n=34), PTC (n=52) and ATC (n=34). In addition, in situ apoptotic cell death was analysed by the TUNEL method. The average Bcl-2 staining score did not differ between PMC and PTC (p>0.05), but was significantly lower in ATC (p
- 30 June 2009
- Published by PAGEPress Publications in European Journal of Histochemistry
- Vol. 53 (2) , e8
Open AccessChanges in the balance between proliferation and apoptosis during the progression of malignancy in thyroid tumours
The aim of this study was to gain better insight into molecular changes which reflect disturbances in the balance between proliferation and apoptosis during progression of thyroid malignancy from papillary microcarcinoma (PMC) via clinically manifest papillary carcinoma (PTC) to anaplastic carcinoma (ATC). The apoptosis related molecules (Bcl-2, Bax) and proliferation related marker (PCNA) were analysed immunohistochemically in 120 archival cases comprising PMC (n=34), PTC (n=52) and ATC (n=34). In addition, in situ apoptotic cell death was analysed by the TUNEL method. The average Bcl-2 staining score did not differ between PMC and PTC (p>0.05), but was significantly lower in ATC (p
Apoptosis and proliferation related molecules (Bcl-2, Bax, p53, PCNA) in papillary microcarcinoma versus papillary carcinoma of the thyroid
To gain a better insight into the differences in biological behaviour between papillary microcarcinoma (PMC) and clinically evident papillary thyroid carcinoma (PTC). Immunohistochemical analysis of apoptosis related molecules (Bcl-2, Bax, p53) and proliferation related marker (PCNA) in 39 archival cases of PMC and 46 cases of PTC. Bcl-2 and Bax were expressed in most PMCs and PTCs. The average Bcl-2 staining score did not differ significantly between PMCs and PTCs (p > 0.05), but the average Bax score was significantly lower in PMCs (p < 0.05). The Bcl-2/Bax ratio was significantly higher in PMCs than in PTCs (p < 0.05). The expression of p53 was similar in PMCs and PTCs, without a correlation with clinical data, but was associated with high Bax expression (p < 0.05) in these cases in both groups. Non-malignant tissue expressed only Bcl-2, but not p53 or Bax. PCNA expression was significantly lower (p < 0.05) in PMC than in PTC and positively correlated with tumour size (p < 0.05). The higher Bcl-2/Bax ratio and lower proliferative activity in PMC suggest differences from PTC in the balance between apoptosis and proliferation. However, the presence of p53 and Bax in PMC indicates malignant potential, and thus PMC should be treated with caution.
Apoptosis and proliferation related molecules (Bcl-2, Bax, p53, PCNA) in papillary microcarcinoma versus papillary carcinoma of the thyroid
To gain a better insight into the differences in biological behaviour between papillary microcarcinoma (PMC) and clinically evident papillary thyroid carcinoma (PTC). Immunohistochemical analysis of apoptosis related molecules (Bcl-2, Bax, p53) and proliferation related marker (PCNA) in 39 archival cases of PMC and 46 cases of PTC. Bcl-2 and Bax were expressed in most PMCs and PTCs. The average Bcl-2 staining score did not differ significantly between PMCs and PTCs (p > 0.05), but the average Bax score was significantly lower in PMCs (p < 0.05). The Bcl-2/Bax ratio was significantly higher in PMCs than in PTCs (p < 0.05). The expression of p53 was similar in PMCs and PTCs, without a correlation with clinical data, but was associated with high Bax expression (p < 0.05) in these cases in both groups. Non-malignant tissue expressed only Bcl-2, but not p53 or Bax. PCNA expression was significantly lower (p < 0.05) in PMC than in PTC and positively correlated with tumour size (p < 0.05). The higher Bcl-2/Bax ratio and lower proliferative activity in PMC suggest differences from PTC in the balance between apoptosis and proliferation. However, the presence of p53 and Bax in PMC indicates malignant potential, and thus PMC should be treated with caution.
- 9 September 2005
- Published by Wiley in Head & Neck
- Vol. 27 (12) , 1049-1055
Galectin‐3 expression in papillary thyroid carcinoma: Relation to histomorphologic growth pattern, lymph node metastasis, extrathyroid invasion, and tumor size
Background.: Galectin‐3 has been recently recognized as a promising presurgical marker of thyroid malignancy.Methods.: Galectin‐3 expression was examined immunohistochemically in 202 specimens of papillary thyroid carcinoma (PTC) in relation to histomorphologic subtypes and clinicopathologic data.Results.: The sensitivity of galectin‐3 immunostaining versus conventional histology was 98% (100 of 102) for classical PTC, 85.2% (46 of 54) for follicular variant, and 50% (23 of 46) for follicular/solid variant of PTC. All cases (n = 36) involving lymph node metastases and 42 of 45 cases with extrathyroid invasion expressed galectin‐3. However, among the galectin‐3–positive cases (n = 169), 133 were without lymph node metastases, and 127 were without extrathyroid invasion. Galectin‐3 expression was not related to the size of intrathyroid PTC.Conclusions.: Galectin‐3 immunohistochemical expression itself is not an indicator of local metastatic spread or extrathyroid invasion of PTC, thus being irrelevant clinically from this aspect. Galectin‐3 is an excellent marker for classical PTC but must be used with caution in diagnosing unconventional variants of PTC because of the possibility of false‐negative results. © 2005 Wiley Periodicals, Inc. Head Neck 27: XXX–XXX, 2005
- 9 September 2005
- Published by Wiley in Head & Neck
- Vol. 27 (12) , 1049-1055
Galectin‐3 expression in papillary thyroid carcinoma: Relation to histomorphologic growth pattern, lymph node metastasis, extrathyroid invasion, and tumor size
Background.: Galectin‐3 has been recently recognized as a promising presurgical marker of thyroid malignancy.Methods.: Galectin‐3 expression was examined immunohistochemically in 202 specimens of papillary thyroid carcinoma (PTC) in relation to histomorphologic subtypes and clinicopathologic data.Results.: The sensitivity of galectin‐3 immunostaining versus conventional histology was 98% (100 of 102) for classical PTC, 85.2% (46 of 54) for follicular variant, and 50% (23 of 46) for follicular/solid variant of PTC. All cases (n = 36) involving lymph node metastases and 42 of 45 cases with extrathyroid invasion expressed galectin‐3. However, among the galectin‐3–positive cases (n = 169), 133 were without lymph node metastases, and 127 were without extrathyroid invasion. Galectin‐3 expression was not related to the size of intrathyroid PTC.Conclusions.: Galectin‐3 immunohistochemical expression itself is not an indicator of local metastatic spread or extrathyroid invasion of PTC, thus being irrelevant clinically from this aspect. Galectin‐3 is an excellent marker for classical PTC but must be used with caution in diagnosing unconventional variants of PTC because of the possibility of false‐negative results. © 2005 Wiley Periodicals, Inc. Head Neck 27: XXX–XXX, 2005
- 1 September 2005
- Vol. 27 (3) , 210-4
Galectin-3 and proliferating cell nuclear antigen (PCNA) expression in papillary thyroid carcinoma.
To examine the relationship between galectin-3 and cell proliferation in thyroid tumor tissue. Galectin-3, a beta-galactoside binding protein, has recently been recognized as a promising molecular marker of thyroid malignancy, due to its high expression in thyroid carcinomas and absence from normal or benign thyroid tissue. However, its exact role in thyroid tumor biology is still unknown. We examined the relationship between galectin-3 and cell proliferation by comparative immunostaining for galectin-3 and proliferating cell nuclear antigen (PCNA) in paraffin-embedded tissues from 126 cases of papillary thyroid carcinoma. Positive cytoplasmic immunostaining for galectin-3 was found in 115 (91.3%) cases. Nuclear staining for PCNA was detectable in 93 (74.4%) cases. A low level of PCNA staining (less than 10% positive cells) was found in 36 (28.6%) cases, moderate staining for PCNA (more than 10% but less than 30% positive cells) in 35 cases (27.8%), while highly increased PCNA expression (more than 30% positive cells) was found in 32 (25.4%) cases. Moderate or strong galectin-3 expression, found in 99 cases, was associated with highly increased PCNA staining in 28.3% of them but with no detectable PCNA expression in 24.3% of them. These results suggest that overexpression of galectin-3 is not clearly related to proliferative activity of papillary thyroid carcinoma cells as assessed by PCNA immunostaining.
- 1 September 2005
- Vol. 27 (3) , 210-4
Galectin-3 and proliferating cell nuclear antigen (PCNA) expression in papillary thyroid carcinoma.
To examine the relationship between galectin-3 and cell proliferation in thyroid tumor tissue. Galectin-3, a beta-galactoside binding protein, has recently been recognized as a promising molecular marker of thyroid malignancy, due to its high expression in thyroid carcinomas and absence from normal or benign thyroid tissue. However, its exact role in thyroid tumor biology is still unknown. We examined the relationship between galectin-3 and cell proliferation by comparative immunostaining for galectin-3 and proliferating cell nuclear antigen (PCNA) in paraffin-embedded tissues from 126 cases of papillary thyroid carcinoma. Positive cytoplasmic immunostaining for galectin-3 was found in 115 (91.3%) cases. Nuclear staining for PCNA was detectable in 93 (74.4%) cases. A low level of PCNA staining (less than 10% positive cells) was found in 36 (28.6%) cases, moderate staining for PCNA (more than 10% but less than 30% positive cells) in 35 cases (27.8%), while highly increased PCNA expression (more than 30% positive cells) was found in 32 (25.4%) cases. Moderate or strong galectin-3 expression, found in 99 cases, was associated with highly increased PCNA staining in 28.3% of them but with no detectable PCNA expression in 24.3% of them. These results suggest that overexpression of galectin-3 is not clearly related to proliferative activity of papillary thyroid carcinoma cells as assessed by PCNA immunostaining.
- 25 July 2005
- Published by Wiley in Histopathology
- Vol. 47 (2) , 209-214
Galectin‐3 expression in papillary microcarcinoma of the thyroid
Aims : Galectin‐3 is a β‐galactoside binding protein, recently recognized as a promising molecular marker of thyroid malignancy. As reported in several studies, galectin‐3 is highly expressed in papillary thyroid carcinoma, but its expression has not been investigated in papillary microcarcinoma, which is a variant of papillary thyroid carcinoma.Methods and results : Using a monoclonal antibody to galectin‐3 and the avidin–biotin–peroxidase complex (ABC) immunohistochemical technique, we analysed galectin‐3 expression in 63 cases of papillary microcarcinoma. The results showed immunohistochemical reactivity for galectin‐3 in 51 (80.9%) cases. Intensity of staining varied from strong or moderate to weak. Galectin‐3 localization was mostly cytoplasmic, but also membranous or nuclear in some cells. Immunohistochemical expression of galectin‐3 was not found in 12 (19.1%) cases. Most galectin‐3 negative microcarcinomas (10/12) were of the non‐classical type, i.e. without papillary architecture. Neither the frequency nor the intensity of a positive reaction was related to tumour size.Conclusions : Galectin‐3 gene is expressed at the protein level in most papillary microcarcinomas, although with slightly lower frequency than that reported for clinically evident papillary thyroid carcinoma. The presence of galectin‐3 in clinically silent microcarcinomas may indicate that galectin‐3 is not related to growth or aggressiveness of papillary thyroid microcarcinomas but rather plays some other role in thyroid tumour biology.
- 25 July 2005
- Published by Wiley in Histopathology
- Vol. 47 (2) , 209-214
Galectin‐3 expression in papillary microcarcinoma of the thyroid
Aims : Galectin‐3 is a β‐galactoside binding protein, recently recognized as a promising molecular marker of thyroid malignancy. As reported in several studies, galectin‐3 is highly expressed in papillary thyroid carcinoma, but its expression has not been investigated in papillary microcarcinoma, which is a variant of papillary thyroid carcinoma.Methods and results : Using a monoclonal antibody to galectin‐3 and the avidin–biotin–peroxidase complex (ABC) immunohistochemical technique, we analysed galectin‐3 expression in 63 cases of papillary microcarcinoma. The results showed immunohistochemical reactivity for galectin‐3 in 51 (80.9%) cases. Intensity of staining varied from strong or moderate to weak. Galectin‐3 localization was mostly cytoplasmic, but also membranous or nuclear in some cells. Immunohistochemical expression of galectin‐3 was not found in 12 (19.1%) cases. Most galectin‐3 negative microcarcinomas (10/12) were of the non‐classical type, i.e. without papillary architecture. Neither the frequency nor the intensity of a positive reaction was related to tumour size.Conclusions : Galectin‐3 gene is expressed at the protein level in most papillary microcarcinomas, although with slightly lower frequency than that reported for clinically evident papillary thyroid carcinoma. The presence of galectin‐3 in clinically silent microcarcinomas may indicate that galectin‐3 is not related to growth or aggressiveness of papillary thyroid microcarcinomas but rather plays some other role in thyroid tumour biology.
- 1 January 2005
- Published by National Library of Serbia in Jugoslovenska medicinska biohemija
- Vol. 24 (2) , 115-119
Assay performance and clinical validation of a radioimmunoassay for serum thyroxine-binding globulin
A radioimmunoassay for the quantitation of serum thyroxine-binding globulin (TBG), RIA TBG (PEG) - INEP, was formed and characterised. Test sensitivity was found to be favorable (2.0 mg/L). The highly satisfactory precision of the assay was reflected in the low coefficients of variation (less than 5%) found for both intra- and interassay precision at three concentrations. Non-specific binding of the labeled antigen was less than 2% of the total binding. Linearity of the assay within the range of the standard curve (0-80.0 mg/L) was excellent (r =0.99) and the analytical recovery of TBG added to serum ranged from 91 to 115%. Reproducibility was checked by determining the concentration of TBG in samples of sera over a period of 32 days from the day of antigen iodination and F
- 1 January 2005
- Published by National Library of Serbia in Jugoslovenska medicinska biohemija
- Vol. 24 (2) , 115-119
Assay performance and clinical validation of a radioimmunoassay for serum thyroxine-binding globulin
A radioimmunoassay for the quantitation of serum thyroxine-binding globulin (TBG), RIA TBG (PEG) - INEP, was formed and characterised. Test sensitivity was found to be favorable (2.0 mg/L). The highly satisfactory precision of the assay was reflected in the low coefficients of variation (less than 5%) found for both intra- and interassay precision at three concentrations. Non-specific binding of the labeled antigen was less than 2% of the total binding. Linearity of the assay within the range of the standard curve (0-80.0 mg/L) was excellent (r =0.99) and the analytical recovery of TBG added to serum ranged from 91 to 115%. Reproducibility was checked by determining the concentration of TBG in samples of sera over a period of 32 days from the day of antigen iodination and F
- 1 January 2005
- Published by National Library of Serbia in Jugoslovenska medicinska biohemija
- Vol. 24 (4) , 241-246
The T4/TBG ratio in healthy subjects and in patients with disorders of thyroid function: correlation with FT4 concentrations
- 1 January 2005
- Published by National Library of Serbia in Jugoslovenska medicinska biohemija
- Vol. 24 (4) , 241-246
The T4/TBG ratio in healthy subjects and in patients with disorders of thyroid function: correlation with FT4 concentrations
- 1 January 2003
- Published by National Library of Serbia in Jugoslovenska medicinska biohemija
- Vol. 22 (4) , 319-323
Carbohydrate characterization of purified thyroxine-binding globulin by lectin blot and isoelectric focusing
The structure of carbohydrate moiety of purified thyroxine-binding globulin (TBG) was examined by lectin blot and isoelectric focusing (IEF). In lectin blot, TBG reacted positively with the following lectins: Sambucus nigra agglutinin (SNA I), Ricinus commuais agglutinin (RCA I), wheat germ lectin (WGA), phytoheamagglutinin (PHA) and pea lectin (PSA). The obtained results indicate that purified TBG contains N-linked oligosaccharide chains consisting of mannose, galactose, N-acetylglucosamine and sialic acid. Isoelectric focusing of TBG at pl 4.2-4.6 revealed three bands, which confirmed that isolated TBG had retained its structure with?out desialylation. Lectin blot analysis and IEF can be considered to be useful tools in the study of TBG glycosylation.
- 1 January 2003
- Published by National Library of Serbia in Jugoslovenska medicinska biohemija
- Vol. 22 (4) , 319-323
Carbohydrate characterization of purified thyroxine-binding globulin by lectin blot and isoelectric focusing
The structure of carbohydrate moiety of purified thyroxine-binding globulin (TBG) was examined by lectin blot and isoelectric focusing (IEF). In lectin blot, TBG reacted positively with the following lectins: Sambucus nigra agglutinin (SNA I), Ricinus commuais agglutinin (RCA I), wheat germ lectin (WGA), phytoheamagglutinin (PHA) and pea lectin (PSA). The obtained results indicate that purified TBG contains N-linked oligosaccharide chains consisting of mannose, galactose, N-acetylglucosamine and sialic acid. Isoelectric focusing of TBG at pl 4.2-4.6 revealed three bands, which confirmed that isolated TBG had retained its structure with?out desialylation. Lectin blot analysis and IEF can be considered to be useful tools in the study of TBG glycosylation.
- Open Access
- 1 January 2003
- Published by National Library of Serbia in Archive of Oncology
- Vol. 11 (3) , 186
Galectin-3: A promising marker of thyroid malignancy
Background: Galectin-3 is an endogenous beta-galactoside binding lectin implicated in neoplastic transformation and tumor progression. High levels of this lectin have recently been found in malignant thyroid tumors, but not in normal or benign thyroid tissue, suggesting galectin-3 as a promising presurgical marker of thyroid malignancy. Methods: We analyzed immunohistochemically galectin-3 expression in thyroid tissue using a monoclonal antibody. The total of 108 tissue specimens included 55 cases of thyroid carcinoma (30 papillary, 15 follicular, and 10 anaplastic type), 15 samples of follicular adenoma, 15 samples of normal thyroid tissue, and 23 thyroid tissue specimens from human fetuses (16 to 37 weeks of intrauterine life). Results: The results showed galectin-3 expression in 20/30 papillary carcinomas, 11/15 follicular carcinomas, 10/10 anaplastic carcinomas, and 4/15 follicular adenomas. Thyroid follicular cells in normal adult and fetal tissue were negative. Conclusions: These results further confirm that galectin-3 expression is a feature of malignant thyroid cells, and that immunohistochemical detection of galectin-3 could be useful in thyroid carcinoma diagnostics. The absence of galectin-3 in thyroid cells during fetal development suggests that galectin-3 is expressed de novo during malignant transformation of thyroid epithelium, thus it should not be considered an oncofetal antigen.
- 1 January 2003
- Published by National Library of Serbia in Archive of Oncology
- Vol. 11 (3) , 186
Open AccessGalectin-3: A promising marker of thyroid malignancy
Background: Galectin-3 is an endogenous beta-galactoside binding lectin implicated in neoplastic transformation and tumor progression. High levels of this lectin have recently been found in malignant thyroid tumors, but not in normal or benign thyroid tissue, suggesting galectin-3 as a promising presurgical marker of thyroid malignancy. Methods: We analyzed immunohistochemically galectin-3 expression in thyroid tissue using a monoclonal antibody. The total of 108 tissue specimens included 55 cases of thyroid carcinoma (30 papillary, 15 follicular, and 10 anaplastic type), 15 samples of follicular adenoma, 15 samples of normal thyroid tissue, and 23 thyroid tissue specimens from human fetuses (16 to 37 weeks of intrauterine life). Results: The results showed galectin-3 expression in 20/30 papillary carcinomas, 11/15 follicular carcinomas, 10/10 anaplastic carcinomas, and 4/15 follicular adenomas. Thyroid follicular cells in normal adult and fetal tissue were negative. Conclusions: These results further confirm that galectin-3 expression is a feature of malignant thyroid cells, and that immunohistochemical detection of galectin-3 could be useful in thyroid carcinoma diagnostics. The absence of galectin-3 in thyroid cells during fetal development suggests that galectin-3 is expressed de novo during malignant transformation of thyroid epithelium, thus it should not be considered an oncofetal antigen.
- Open Access
- 1 January 2003
- Published by National Library of Serbia in Archive of Oncology
- Vol. 11 (2) , 71-74
Galectin-3 expression in medullary thyroid carcinoma in relation to tumor progression
BACKGROUND: Galectin-3, a lectin with specificity for beta galactosides, is believed to be implicated in multiple biological processes through interactions with complementary glycoconjugates. Alterations in galectin-3 expression are observed in a variety of human tumors. In thyroid, this lectin has been found to be highly expressed in malignancies of epithelial origin. We analyzed galectin-3 expression in medullary thyroid carcinoma (MTC). MATERIALS AND METHODS: An immunohistochemical study using monoclonal antibody was performed on paraffin sections of twenty cases of sporadic MTC comprising ten cases without and ten cases with lymph node metastases at the time of surgery. RESULTS: Positive cytoplasmic staining for galectin-3 was found in 16/20 cases, but varied in intensity and distribution from weak/focal (7/16) to moderate (7/16) or strong (2/16). Advanced stage of MTC (with lymph node metastases at the time of surgery) showed moderate to strong galectin-3 expression more frequently (8/10) than cases without lymph node metastases (1/10). CONCLUSION: These findings suggest that galectin-3 expression is associated with the advanced stage of disease and that this lection might play a role in the pathobiology of MTC.
- 1 January 2003
- Published by National Library of Serbia in Archive of Oncology
- Vol. 11 (2) , 71-74
Open AccessGalectin-3 expression in medullary thyroid carcinoma in relation to tumor progression
BACKGROUND: Galectin-3, a lectin with specificity for beta galactosides, is believed to be implicated in multiple biological processes through interactions with complementary glycoconjugates. Alterations in galectin-3 expression are observed in a variety of human tumors. In thyroid, this lectin has been found to be highly expressed in malignancies of epithelial origin. We analyzed galectin-3 expression in medullary thyroid carcinoma (MTC). MATERIALS AND METHODS: An immunohistochemical study using monoclonal antibody was performed on paraffin sections of twenty cases of sporadic MTC comprising ten cases without and ten cases with lymph node metastases at the time of surgery. RESULTS: Positive cytoplasmic staining for galectin-3 was found in 16/20 cases, but varied in intensity and distribution from weak/focal (7/16) to moderate (7/16) or strong (2/16). Advanced stage of MTC (with lymph node metastases at the time of surgery) showed moderate to strong galectin-3 expression more frequently (8/10) than cases without lymph node metastases (1/10). CONCLUSION: These findings suggest that galectin-3 expression is associated with the advanced stage of disease and that this lection might play a role in the pathobiology of MTC.